Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05078086
Other study ID # 2021-0486
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 18, 2021
Est. completion date January 20, 2024

Study information

Verified date September 2021
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Dawei Sun, Doctor
Phone +86 19557123452
Email sundaweide@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Avoidance of unnecessary blood transfusions has always been a focus of clinical research. The rate of perioperative red blood cell transfusion in patients undergoing cardiac surgery under cardiopulmonary bypass reaches between 50-70%, and the intraoperative red blood cell transfusion rate is 30-50%. Regarding whether and when to perform a blood transfusion, it is necessary to comprehensively consider the benefits and risks brought by blood transfusion. Previous studies on blood transfusion strategies have mainly focused on the hemoglobin threshold, but the hemoglobin level does not fully reflect the level of tissue oxygenation. Mixed venous blood oxygen saturation has been widely studied as a valuable indicator reflecting the balance of oxygen delivery and oxygen consumption. But due to the difficulty of placing a pulmonary artery floating catheter for monitoring, its clinical application is limited. Central venous oxygen saturation requires only a small collection of blood samples, which can reflect the oxygen saturation of the superior vena cava, and studies have shown that it can effectively guide the blood transfusion of patients undergoing cardiac surgery. Existing studies have shown that in critically ill patients, the use of arterial-venous oxygen difference > 3.7 mL as an indicator to guide blood transfusion can lead to a higher 90-day survival rate. However, the relationship between the arterial-venous oxygen difference and the incidence of adverse events in cardiac surgery patients under CPB remains unclear. Whether increasing the arterial-venous oxygen difference during surgery can reduce the incidence of postoperative adverse events remains to be clarified. This study intends to collect intraoperative arterial blood and central venous blood samples from cardiac surgery patients undergoing CPB, and analyze the relationship between arterial-venous oxygen difference and the incidence of postoperative adverse events.


Description:

The >18 y/o patients who undergo cardiac surgery with cardiopulmonary bypass and with a preoperative additive EuroSCORE I≥ 6 are enrolled. Blood samples will be collected through arteries and central venous at the following intraoperative time points: before CPB, during CPB, after CPB, before transfusion, and after transfusion. The observation will end by hospital discharge or 28 days after surgery, whichever came first. The follow-up will continue to one year after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 314
Est. completion date January 20, 2024
Est. primary completion date January 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Over 18 years old - Cardiovascular surgery patients with cardiopulmonary bypass - Preoperative EuroSCORE I=6(European System for Cardiac Operative Risk Evaluation) - Obtained informed consent Exclusion Criteria: - Patients who cannot accept blood products - Patients who refuse to accept transfusion - Patients with autologous blood reserve before surgery - Patients who are going to receive heart transplantation or have undergone heart transplantation - Patients who have undergone ventricular assist device implantation surgery - Patients who refuse to participate in this trial

Study Design


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
China The Second Affiliated Hospital of Zhejiang University anesthesiology department Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite outcome of mortality and serious morbidity (cardiac, renal, and neurological events) Composite incidence of any one of the following events occurring during the hospitalization : (1) all-cause mortality; (2) myocardial infarction; (3) new renal failure requiring dialysis; or (4) new focal neurological deficit (stroke) From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Incidence of any independent component of the primary outcome Incidence of any independent component of the primary outcome (all-cause mortality, myocardial infarction, new renal failure requiring dialysis, and new focal neurological deficit (stroke)) From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Blood product transfusion Time, category, and volume of blood product transfusion From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Length of stay in ICU Length of stay in ICU after surgery From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Total length of hospital stay after surgery Total length of hospital stay after surgery From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Duration of mechanical ventilation after surgery Total length of hospital stay after surgery From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Occurrence of low cardiac output after surgery Need for two or more inotropes for 24 hours or more, intra-aortic balloon pump postoperatively or ventricular assist device From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Infection Infection will be defined as septic shock with positive blood cultures; pneumonia defined as autopsy diagnosis or roentgenographic infiltrate and at least two of the following three criteria: fever, leukocytosis, and positive sputum culture; and/or deep sternal or leg wound infection requiring intravenous antibiotics and/or surgical debridement From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Gut infarction confirmed by imaging, autopsy, or through surgical means From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Acute kidney injury AKI defined by the KDIGO From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Seizures Defined as generalized or focal tonic-clonic movements consistent with seizure; or EEG demonstrating epileptiform discharges; or diagnosis of seizures by neurologist or neurosurgeon consultation From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Delirium Based on one of the following criteria: CAM-ICU/ CAM (even on 1 occasion) or ICDSC > 3 or more than one dose of haloperidol or similar antipsychotic drug or documented delirium by neurologist or neurosurgeon or psychiatrist consultation From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Encephalopathy Defined as unexpected delayed awakening or severely altered mental status (unconscious despite no sedative medication for more than 5 days), or encephalopathy documented by neurologist or neurosurgeon or psychiatrist consultation From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
Secondary Reoperation rate The rate of reoperation From the start of surgery until hospital discharge or postoperative day 28, whichever comes first
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2